Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 62pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 45Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26abemaciclib 25Specimen Handling 25130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × vistusertib × Breast × Clear all
NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

UNICANCER

Phase 2 Active not recruiting
1,460 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡